CLL/SLL

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings

Global Trial in APG2575 for Patients With CLL/SLL

LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies

Current Status of BTKi Treatment for CLL/SLL in China

A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy

A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib

the Real World Study of Orelabrutinib in the Treatment of CLL/SLL

Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma

Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL

Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies